SPMS- US Overview
Secondary Progressive Multiple Sclerosis (SPMS) as a disease area has a high market potential but not many drugs are approved and hence has a high unmet need.
The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in the US market, highlights the SPMS epidemiology in the US, elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the detailed market sizing drug wise in the US in value sales and patient numbers along with forecast. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of a SPMS patient, Symptoms of SPMS patient, and disease progression in a SPMS patient.
The report further highlights the multiple methods through which the patient can be diagnosed for SPMS. The next part of the report consists of SPMS epidemiology and prevalence in the US. The epidemiology for SPMS indication has been forecasted till 2024 as well in the report. The next part of the report highlights the importance of factors influencing the physician prescription decisions in SPMS like efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.
The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the SPMS market. The report further details the drug attribute analysis drug wise on each parameter considered important in the prescription of SPMS drugs. The report also covers the other products which are currently in the pipeline for SPMS and other progressive forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise in the US both in terms of value sales and patient numbers. The drugs have been forecasted till 2030 both for value sales and patient numbers in the US
The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in the US market, highlights the SPMS epidemiology in the US, elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the detailed market sizing drug wise in the US in value sales and patient numbers along with forecast. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of a SPMS patient, Symptoms of SPMS patient, and disease progression in a SPMS patient.
The report further highlights the multiple methods through which the patient can be diagnosed for SPMS. The next part of the report consists of SPMS epidemiology and prevalence in the US. The epidemiology for SPMS indication has been forecasted till 2024 as well in the report. The next part of the report highlights the importance of factors influencing the physician prescription decisions in SPMS like efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.
The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the SPMS market. The report further details the drug attribute analysis drug wise on each parameter considered important in the prescription of SPMS drugs. The report also covers the other products which are currently in the pipeline for SPMS and other progressive forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise in the US both in terms of value sales and patient numbers. The drugs have been forecasted till 2030 both for value sales and patient numbers in the US
Multiple Sclerosis Definition
Types of MS
SPMS definition
Causes of SPMS
Profile of SPMS patient
Symptoms of SPMS patient
Disease progression and impact on QoL
Disease diagnosis
Disease Epidemiology in the US
Factors influencing Physician prescription decision
DMTs for SPMS
Drug Attribute analysis
Pipeline products in SPMS
SPMS Market sizing drug wise including value sales and patient numbers in the US
Types of MS
SPMS definition
Causes of SPMS
Profile of SPMS patient
Symptoms of SPMS patient
Disease progression and impact on QoL
Disease diagnosis
Disease Epidemiology in the US
Factors influencing Physician prescription decision
DMTs for SPMS
Drug Attribute analysis
Pipeline products in SPMS
SPMS Market sizing drug wise including value sales and patient numbers in the US
